CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.
Approval Alert | Pafolacianine for Ovarian Cancer Detection During Surgery
Philip S. Low, PhD, discusses the obstacles he overcame while creating pafolacianine and what other cancers he hopes will be improved with the use of this agent.
Imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
3
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
